Identification

Name
Guanfacine
Accession Number
DB01018  (APRD00075)
Type
Small Molecule
Groups
Approved, Investigational
Description

A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]

Structure
Thumb
Synonyms
  • Estulic
  • Guanfacina
  • Guanfacinum
External IDs
SPD 503
Product Ingredients
IngredientUNIICASInChI Key
Guanfacine HydrochloridePML56A160O29110-48-3DGFYECXYGUIODH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IntunivTablet, extended release3 mgOralShire2015-09-17Not applicableEu
IntunivKitShire2009-09-02Not applicableUs
IntunivTablet, extended release1 mg/1OralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivTablet, extended release1 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release2 mg/1OralShire2009-09-02Not applicableUs54092 0515 02 nlmimage10 071603e0
IntunivTablet, extended release2 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release4 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release4 mg/1OralShire2009-09-02Not applicableUs54092 0519 02 nlmimage10 fd15feaf
IntunivTablet, extended release2 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release1 mg/1OralShire2009-09-02Not applicableUs54092 0513 02 nlmimage10 011600e0
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GuanfacineTablet2 mg/1OralEpic Pharma, LLC2013-12-02Not applicableUs
GuanfacineTablet, extended release1 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
GuanfacineTablet1 mg/1OralPhysicians Total Care, Inc.1995-10-17Not applicableUs
GuanfacineTablet, extended release3 mg/1OralTeva2015-06-02Not applicableUs00093 5963 01 nlmimage10 cd43e6ff
GuanfacineTablet, extended release2 mg/1OralActavis Pharma Company2014-12-01Not applicableUs00228 2851 11 nlmimage10 113e08a0
GuanfacineTablet2 mg/1OralActavis Pharma Company1995-10-17Not applicableUs00591 0453 01 nlmimage10 7207b90d
GuanfacineTablet1 mg/1OralMylan Pharmaceuticals1997-01-27Not applicableUs
GuanfacineTablet, extended release4 mg/1OralActavis Pharma Company2014-12-01Not applicableUs00228 2855 11 nlmimage10 0b4085f4
GuanfacineTablet2 mg/1OralPura Cap Laboratories Llc Dba Blu Pharmaceuticals2016-11-14Not applicableUs
GuanfacineTablet2 mg/1OralGolden State Medical Supply2017-03-07Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GuanfacineTablet, extended release1 mg/1OralSun Pharmaceutical Industries Limited2017-09-01Not applicableUs
GuanfacineTablet, extended release3 mg/1OralSun Pharmaceutical Industries Limited2017-09-01Not applicableUs
GuanfacineTablet, extended release2 mg/1OralSun Pharmaceutical Industries Limited2017-09-01Not applicableUs
GuanfacineTablet, extended release4 mg/1OralSun Pharmaceutical Industries Limited2017-09-01Not applicableUs
International/Other Brands
Estulic (Egis)
Categories
UNII
30OMY4G3MK
CAS number
29110-47-2
Weight
Average: 246.093
Monoisotopic: 245.012267339
Chemical Formula
C9H9Cl2N3O
InChI Key
INJOMKTZOLKMBF-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
IUPAC Name
N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide
SMILES
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl

Pharmacology

Indication

For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.

Structured Indications
Pharmacodynamics

Guanfacine is a phenylacetyl-guanidine derivative hypotensive and a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension.

Mechanism of action

Guanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects.

TargetActionsOrganism
AAlpha-2A adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
binder
Human
Absorption

Rapid and complete, with an oral bioavailability of approximately 80%.

Volume of distribution
  • 6.3 L/kg
Protein binding

Approximately 70% bound to plasma proteins, independent of drug concentration.

Metabolism

Hepatic

Route of elimination

In individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine.

Half life

17 hours (range 10-30 hours)

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD50=165mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanfacine.Experimental
AbirateroneThe metabolism of Guanfacine can be decreased when combined with Abiraterone.Approved
AcebutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcemetacinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Guanfacine.Approved, Investigational
AliskirenGuanfacine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanGuanfacine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineGuanfacine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Guanfacine.Illicit, Withdrawn
AmiodaroneThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Guanfacine.Approved
AmlodipineGuanfacine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineAmoxapine may decrease the antihypertensive activities of Guanfacine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Guanfacine.Approved, Illicit
AprepitantThe serum concentration of Guanfacine can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Guanfacine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
AtazanavirThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Guanfacine.Approved
BarnidipineGuanfacine may increase the antihypertensive activities of Barnidipine.Approved
BefunololGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilGuanfacine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideGuanfacine may increase the hypotensive activities of Bendroflumethiazide.Approved
Benzylpenicilloyl PolylysineGuanfacine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilGuanfacine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololGuanfacine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Guanfacine.Approved
BevantololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineGuanfacine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostGuanfacine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Guanfacine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Guanfacine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Guanfacine may increase the hypotensive activities of BQ-123.Investigational
BretyliumGuanfacine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Guanfacine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Guanfacine.Experimental
BucindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolGuanfacine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Guanfacine.Investigational
BupranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
CadralazineGuanfacine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineGuanfacine may increase the hypotensive activities of Cafedrine.Investigational
CandesartanGuanfacine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilGuanfacine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilGuanfacine may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe metabolism of Guanfacine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilGuanfacine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Guanfacine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarteololGuanfacine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolGuanfacine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Guanfacine can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Guanfacine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideGuanfacine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneGuanfacine may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Guanfacine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineGuanfacine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilGuanfacine may increase the hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.Approved
CitalopramThe metabolism of Guanfacine can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Guanfacine can be decreased when combined with Clemastine.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Guanfacine.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Guanfacine.Approved
CloranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Guanfacine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Guanfacine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Guanfacine.Approved, Investigational
CrisaboroleThe metabolism of Guanfacine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Guanfacine can be decreased when combined with Crizotinib.Approved
CryptenamineGuanfacine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Guanfacine.Approved
CyclopenthiazideGuanfacine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideGuanfacine may increase the hypotensive activities of Cyclothiazide.Approved
DabrafenibThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Guanfacine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinGuanfacine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilGuanfacine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Guanfacine can be decreased when combined with Delavirdine.Approved
DeserpidineGuanfacine may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Guanfacine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Guanfacine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Guanfacine.Experimental
DiethylnorspermineGuanfacine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineGuanfacine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Guanfacine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Guanfacine can be decreased when combined with Diltiazem.Approved
DorzolamideGuanfacine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Guanfacine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Guanfacine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Guanfacine.Approved
DoxycyclineThe metabolism of Guanfacine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Guanfacine can be decreased when combined with Dronedarone.Approved
EfavirenzThe metabolism of Guanfacine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineGuanfacine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilGuanfacine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatGuanfacine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineGuanfacine may increase the hypotensive activities of Endralazine.Experimental
EnzalutamideThe serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.Approved
EpanololGuanfacine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EpoprostenolGuanfacine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanGuanfacine may increase the hypotensive activities of Eprosartan.Approved
ErythromycinThe metabolism of Guanfacine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Guanfacine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Guanfacine.Investigational
EsmololGuanfacine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EsomeprazoleThe metabolism of Guanfacine can be decreased when combined with Esomeprazole.Approved, Investigational
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
EtravirineThe metabolism of Guanfacine can be decreased when combined with Etravirine.Approved
FelodipineGuanfacine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamGuanfacine may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidGuanfacine may increase the hypotensive activities of Ferulic acid.Experimental
FloxuridineThe metabolism of Guanfacine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Guanfacine can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Guanfacine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvastatinThe metabolism of Guanfacine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Guanfacine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Guanfacine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilGuanfacine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Guanfacine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Guanfacine can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Guanfacine can be decreased when combined with Gemfibrozil.Approved
GuanabenzGuanfacine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanfacine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineGuanfacine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanfacine may increase the hypotensive activities of Guanethidine.Approved
GuanoclorGuanfacine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzGuanfacine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanGuanfacine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Guanfacine.Experimental
HexamethoniumGuanfacine may increase the hypotensive activities of Hexamethonium.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Guanfacine.Approved, Investigational
HydralazineGuanfacine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideGuanfacine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideGuanfacine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IdelalisibThe serum concentration of Guanfacine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Guanfacine can be decreased when combined with Imatinib.Approved
ImidaprilGuanfacine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Guanfacine.Approved
IndapamideGuanfacine may increase the hypotensive activities of Indapamide.Approved
IndenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Guanfacine can be increased when it is combined with Indinavir.Approved
IndoraminGuanfacine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanfacine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Guanfacine.Experimental
IproniazidIproniazid may increase the hypotensive activities of Guanfacine.Withdrawn
IrbesartanThe metabolism of Guanfacine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Guanfacine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Guanfacine.Approved
IsoniazidThe metabolism of Guanfacine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Guanfacine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Guanfacine can be increased when it is combined with Ivacaftor.Approved
KetanserinGuanfacine may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Guanfacine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineGuanfacine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololGuanfacine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LatanoprostGuanfacine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Guanfacine can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineGuanfacine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LinsidomineGuanfacine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilGuanfacine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LobeglitazoneThe metabolism of Guanfacine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofepramineLofepramine may decrease the antihypertensive activities of Guanfacine.Experimental
LofexidineGuanfacine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Guanfacine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Guanfacine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Guanfacine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Guanfacine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Guanfacine can be decreased when it is combined with Lumacaftor.Approved
MacitentanGuanfacine may increase the hypotensive activities of Macitentan.Approved
ManidipineGuanfacine may increase the hypotensive activities of Manidipine.Approved, Investigational
MecamylamineMecamylamine may increase the hypotensive activities of Guanfacine.Approved
MepindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MethoserpidineGuanfacine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaGuanfacine may increase the hypotensive activities of Methyldopa.Approved
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
MetipranololGuanfacine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneGuanfacine may increase the hypotensive activities of Metolazone.Approved
MetoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineGuanfacine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilGuanfacine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Guanfacine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Guanfacine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Guanfacine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Guanfacine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Guanfacine.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Guanfacine.Approved
MitotaneThe serum concentration of Guanfacine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Guanfacine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Guanfacine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilGuanfacine may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Guanfacine.Approved, Investigational
MoxonidineGuanfacine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineGuanfacine may increase the hypotensive activities of Muzolimine.Experimental
NadololGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilGuanfacine may increase the hypotensive activities of Naftopidil.Investigational
NebivololGuanfacine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Guanfacine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Guanfacine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Guanfacine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Guanfacine.Withdrawn
NicardipineThe metabolism of Guanfacine can be decreased when combined with Nicardipine.Approved
NicorandilGuanfacine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineGuanfacine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Guanfacine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineGuanfacine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineGuanfacine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineGuanfacine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Guanfacine.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Guanfacine.Approved
ObinutuzumabGuanfacine may increase the hypotensive activities of Obinutuzumab.Approved
OlaparibThe metabolism of Guanfacine can be decreased when combined with Olaparib.Approved
OlmesartanGuanfacine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OmapatrilatGuanfacine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Guanfacine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolOpipramol may decrease the antihypertensive activities of Guanfacine.Investigational
OsimertinibThe serum concentration of Guanfacine can be increased when it is combined with Osimertinib.Approved
OxprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PalbociclibThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the hypotensive activities of Guanfacine.Approved
PenbutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumGuanfacine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Guanfacine.Approved, Investigational
PerindoprilGuanfacine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Guanfacine.Approved
PhenobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineGuanfacine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhentolamineGuanfacine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PinacidilGuanfacine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Guanfacine.Approved
Platelet Activating FactorGuanfacine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazideGuanfacine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Guanfacine.Approved
PrimidoneThe serum concentration of Guanfacine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Guanfacine.Approved
PropranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Guanfacine.Approved
PyrimethamineThe metabolism of Guanfacine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilGuanfacine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineThe metabolism of Guanfacine can be decreased when combined with Quinine.Approved
RamiprilGuanfacine may increase the hypotensive activities of Ramipril.Approved
RanolazineThe metabolism of Guanfacine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Guanfacine.Approved
RemikirenGuanfacine may increase the hypotensive activities of Remikiren.Approved
RescinnamineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Guanfacine.Approved, Investigational
RifabutinThe serum concentration of Guanfacine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Guanfacine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Guanfacine can be decreased when it is combined with Rifapentine.Approved
RilmenidineGuanfacine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatGuanfacine may increase the hypotensive activities of Riociguat.Approved
RituximabGuanfacine may increase the hypotensive activities of Rituximab.Approved
RucaparibThe metabolism of Guanfacine can be decreased when combined with Rucaparib.Approved, Investigational
SaprisartanGuanfacine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Sarilumab.Approved
SecobarbitalThe metabolism of Guanfacine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Guanfacine.Approved, Investigational, Vet Approved
SelexipagGuanfacine may increase the hypotensive activities of Selexipag.Approved
SertralineThe metabolism of Guanfacine can be decreased when combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Guanfacine.Approved
SiltuximabThe serum concentration of Guanfacine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Guanfacine can be increased when it is combined with Simeprevir.Approved
SitaxentanGuanfacine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Guanfacine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilGuanfacine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Guanfacine.Approved
St. John's WortThe serum concentration of Guanfacine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Guanfacine can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Guanfacine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
TalinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
TelaprevirThe serum concentration of Guanfacine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Guanfacine can be increased when it is combined with Telithromycin.Approved
TelmisartanGuanfacine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilGuanfacine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Guanfacine.Approved
TerlipressinGuanfacine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololGuanfacine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrahydropalmatineGuanfacine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineGuanfacine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineTianeptine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
TiboloneGuanfacine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Guanfacine can be decreased when combined with Ticlopidine.Approved
TicrynafenGuanfacine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololGuanfacine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TocilizumabThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.Approved
TolazolineGuanfacine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.Approved
TolonidineGuanfacine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Guanfacine.Approved
TopiramateThe metabolism of Guanfacine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Guanfacine can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideGuanfacine may increase the hypotensive activities of Torasemide.Approved
TrandolaprilGuanfacine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanfacine.Experimental
TranylcypromineThe metabolism of Guanfacine can be decreased when combined with Tranylcypromine.Approved
TravoprostGuanfacine may increase the hypotensive activities of Travoprost.Approved
TreprostinilGuanfacine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideGuanfacine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinGuanfacine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanGuanfacine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Guanfacine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
UnoprostoneGuanfacine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may decrease the vasoconstricting activities of Guanfacine.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Guanfacine.Approved, Investigational
ValsartanThe metabolism of Guanfacine can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Guanfacine.Approved
VemurafenibThe serum concentration of Guanfacine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Guanfacine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Guanfacine can be decreased when combined with Verapamil.Approved
VincamineGuanfacine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineGuanfacine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Guanfacine can be increased when it is combined with Voriconazole.Approved, Investigational
XipamideGuanfacine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Guanfacine.Approved, Vet Approved
ZafirlukastThe metabolism of Guanfacine can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.Approved
ZofenoprilGuanfacine may increase the hypotensive activities of Zofenopril.Experimental
ZucapsaicinThe metabolism of Guanfacine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,632,645.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015153
KEGG Compound
C07037
PubChem Compound
3519
PubChem Substance
46506169
ChemSpider
3399
BindingDB
81984
ChEBI
5558
ChEMBL
CHEMBL862
Therapeutic Targets Database
DAP000900
PharmGKB
PA449825
IUPHAR
522
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Guanfacine
ATC Codes
C02AC02 — Guanfacine
AHFS Codes
  • 24:08.16 — Central Alpha-agonists

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentAlcohol Dependent / Cocaine Dependent1
1CompletedTreatmentCannabis Dependence1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2Active Not RecruitingOtherSmoking1
2Active Not RecruitingTreatmentCessation, Smoking1
2Active Not RecruitingTreatmentSmoking1
2CompletedNot AvailableCocaine Related Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity2
2CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Separation Anxiety / Social Phobia1
2CompletedTreatmentHemispatial Neglect / Strokes1
2CompletedTreatmentSchizotypal Personality Disorder / SPD1
2RecruitingTreatmentAlcohol Drinking1
3CompletedTreatmentAdhd3
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
3CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
3CompletedTreatmentAttention-Deficit/Hyperactivity Disorder2
3CompletedTreatmentGilles de la Tourette's Syndrome1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
4Active Not RecruitingTreatmentObstructive Sleep Apnea (OSA)1
4CompletedBasic ScienceAttention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentAdult Attention-Deficit Hyperactivity Disorder1
4CompletedTreatmentAttention Deficit Disorder (ADD) / Childhood Aggression / Intermittent Explosive Disorder / Oppositional Defiant Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity2
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Deficient Emotional Self-Regulation (DESR)1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Reading Disability1
4CompletedTreatmentAttention-Deficit/Hyperactivity Disorder1
4CompletedTreatmentGilles de la Tourette's Syndrome / Tourette's Disorder1
4CompletedTreatmentPervasive Development Disorders1
4Not Yet RecruitingTreatmentStress Disorders1
4RecruitingTreatmentPain, Chronic1
4TerminatedTreatmentAttention Deficit Disorder (ADD) / Attention-Deficit/Hyperactivity Disorder / Sleep disorders and disturbances / Sleeplessness1
4TerminatedTreatmentPersonality Disorders / Schizotypal Personality Disorder1
4Unknown StatusTreatmentCognitive Impairments / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedBasic ScienceNMDA Receptor Function1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity / Autistic Disorder / Pervasive Development Disorders1
Not AvailableCompletedTreatmentCognitive Aging1
Not AvailableEnrolling by InvitationNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableNot Yet RecruitingBasic ScienceAdhd1
Not AvailableRecruitingTreatmentAttention Deficit Hyperactivity Disorder (ADHD)2
Not AvailableRecruitingTreatmentPain, Chronic1
Not AvailableRecruitingTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableUnknown StatusTreatmentBorderline Personality Disorder (BPD)1

Pharmacoeconomics

Manufacturers
  • Shire development inc
  • Amneal pharmaceutical
  • Mikah pharma llc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
  • Promius pharma llc
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2 mg/1
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral1 mg/1
Tablet, film coated, extended releaseOral2 mg/1
Tablet, film coated, extended releaseOral3 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Kit
Tablet, extended releaseOral1 mg
Tablet, extended releaseOral2 mg
Tablet, extended releaseOral3 mg
Tablet, extended releaseOral4 mg
Prices
Unit descriptionCostUnit
Intuniv 1 mg 24 Hour tablet5.72USD tablet
Intuniv 2 mg 24 Hour tablet5.72USD tablet
Intuniv 3 mg 24 Hour tablet5.72USD tablet
Intuniv 4 mg 24 Hour tablet5.72USD tablet
Intuniv er 1 mg tablet5.5USD tablet
Intuniv er 2 mg tablet5.5USD tablet
Intuniv er 3 mg tablet5.5USD tablet
Intuniv er 4 mg tablet5.5USD tablet
Tenex 2 mg tablet4.3USD tablet
Tenex 1 mg tablet2.9USD tablet
Guanfacine HCl 2 mg tablet1.22USD tablet
Guanfacine 2 mg tablet1.18USD tablet
Guanfacine HCl 1 mg tablet0.91USD tablet
Guanfacine 1 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5854290Yes1996-03-212016-03-21Us
US6811794Yes2003-01-042023-01-04Us
US6287599Yes2001-06-202021-06-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)213-216U.S. Patent 3,632,645.
water solubility1892 mg/LNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP2.28ALOGPS
logP1.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.97 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.63 m3·mol-1ChemAxon
Polarizability21.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9313
Blood Brain Barrier+0.9567
Caco-2 permeable-0.5101
P-glycoprotein substrateNon-substrate0.6778
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9833
Renal organic cation transporterNon-inhibitor0.6443
CYP450 2C9 substrateNon-substrate0.7572
CYP450 2D6 substrateNon-substrate0.7948
CYP450 3A4 substrateNon-substrate0.6475
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8893
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7376
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6619
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8107
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.7408 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.9285
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Imines / Hydrocarbon derivatives
Substituents
1,3-dichlorobenzene / Aryl chloride / Aryl halide / Carboximidamide / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Organic nitrogen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
acetamides (CHEBI:5558)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF: The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000 Sep;23(3):240-9. [PubMed:10942848]
  2. Sagvolden T: The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct. 2006 Dec 15;2:41. [PubMed:17173664]
  3. Yuan R, Wu Z, Kostenyuk IA, Burns JK: G-protein-coupled alpha2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase. J Exp Bot. 2005 Jul;56(417):1867-75. Epub 2005 May 31. [PubMed:15928018]
  4. Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. [PubMed:11164065]
  5. Millan MJ: Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice. Eur J Pharmacol. 1992 May 14;215(2-3):355-6. [PubMed:1356794]
  6. Stahl SM: Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar;71(3):223-4. doi: 10.4088/JCP.09bs05899pur. [PubMed:20331927]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:53